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Abstract
Multi-minicore Disease (MmD) is a recessively inherited neuromuscular disorder characterized by
multiple cores on muscle biopsy and clinical features of a congenital myopathy. Prevalence is
unknown. Marked clinical variability corresponds to genetic heterogeneity: the most instantly
recognizable classic phenotype characterized by spinal rigidity, early scoliosis and respiratory
impairment is due to recessive mutations in the selenoprotein N (SEPN1) gene, whereas recessive
mutations in the skeletal muscle ryanodine receptor (RYR1) gene have been associated with a wider
range of clinical features comprising external ophthalmoplegia, distal weakness and wasting or
predominant hip girdle involvement resembling central core disease (CCD). In the latter forms,
there may also be a histopathologic continuum with CCD due to dominant RYR1 mutations,
reflecting the common genetic background. Pathogenetic mechanisms of RYR1-related MmD are
currently not well understood, but likely to involve altered excitability and/or changes in calcium
homeoestasis; calcium-binding motifs within the selenoprotein N protein also suggest a possible
role in calcium handling. The diagnosis of MmD is based on the presence of suggestive clinical
features and multiple cores on muscle biopsy; muscle MRI may aid genetic testing as patterns of
selective muscle involvement are distinct depending on the genetic background. Mutational analysis
of the RYR1 or the SEPN1 gene may provide genetic confirmation of the diagnosis. Management is
mainly supportive and has to address the risk of marked respiratory impairment in SEPN1-related
MmD and the possibility of malignant hyperthermia susceptibility in RYR1-related forms. In the
majority of patients, weakness is static or only slowly progressive, with the degree of respiratory
impairment being the most important prognostic factor.
Disease name(s)
Multi-minicore Disease; Minicore myopathy; Multicore
myopathy; Multiminicore myopathy; Minicore myopathy
with external ophthalmoplegia; Multicore myopathy with
external ophthalmoplegia; Multiminicore disease with
external ophthalmoplegia
Definition
Multi-minicore Disease (MmD) is an inherited neu-
romuscular disorder defined by a) multiple areas with
reduced oxidative activity running along an only limited
extent of the longitudinal axis of the muscle fibre ("mini-
cores") and b) clinical features of a congenital myopathy.
The condition was originally reported in a family with two
affected siblings and suggestive histopathological findings
[1]; various different designations ("Minicore myopathy",
"Multicore myopathy", "Multiminicore myopathy",
"Minicore myopathy with external ophthalmoplegia",
"Multicore myopathy with external ophthalmoplegia",
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"Multiminicore disease with external ophthalmoplegia")
have been assigned to cases with similar histopathological
features and reflect the wide variability of both core
appearance on muscle biopsy and associated clinical find-
ings.
Epidemiology
Epidemiological data are only available for the congenital
myopathies as a group but not for individual conditions.
The incidence of all congenital myopathies is estimated at
around 0.06/1,000 live births, or onetenth of all cases of
neuromuscular disorders [2]. Regional studies in North-
ern Ireland [3] and Western Sweden [4] suggest a preva-
lence between 3.5 – 5.0/100,000 in a Paediatric
population.
Forms of MmD due to recessive mutations in the seleno-
protein N (SEPN1) gene are probably rarer than those due
to mutations in the skeletal muscle ryanodine receptor
(RYR1) gene (personal observation), as mutations in the
latter gene appear to be the most common genetic cause
of a wide variety of congenital myopathies including cen-
tral core disease (CCD) [5], certain forms of centronuclear
myopathy (CNM) [6] and specific subgroups of MmD.
Clinical description
Presentation of MmD is usually in infancy or childhood
with hypotonia or proximal weakness; prenatal onset
with reduced fetal movements and polyhydramnios has
also been recognized [7,8]. Few cases with onset in adult
life have been reported in the premolecular area, occa-
sionally associated with progressive muscle weakness and
respiratory or cardiac failure [9-12].
Clinical features associated with minicores on muscle
biopsy are markedly heterogeneous:
spinal rigidity, scoliosis and respiratory impairment are
the hallmark of the most instantly recognizable, classic
phenotype of MmD [7,8,13]; onset is usually early in life
and feeding difficulties with failure to thrive may be a pre-
senting feature. A high-pitched voice and myopathic facial
features are common, occasionally associated with a high-
arched or cleft palate. Axial muscle weakness, particularly
affecting neck and trunk flexors, is prominent, and failure
to acquire head control may be an early sign. Proximal
muscle groups, particularly those of the shoulder girdle,
are more affected than distal muscles. Muscle wasting
mainly affects axial groups, the shoulder girdle and the
inner thigh ("bracket-like appearance"). A progressive
scoliosis, often associated with lateral trunk deviation,
and respiratory impairment have typically evolved by the
second decade. Respiratory impairment may lead to sec-
ondary cardiac failure [7,8,14-16] and is often grossly out
of proportion to the overall degree of weakness.
A subset of patients with a distribution of weakness and
wasting similar to the classic phenotype show additional
extra-ocular muscle involvement (MmD with external
ophthalmoplegia), pronounced on abduction and
upward gaze, occasionally evolving over time [7,17-21].
However, respiratory impairment is usually milder than
in the classic form, with the exception of the most severely
affected neonatal cases [22]. Predominant hip girdle
weakness with relative sparing of respiratory and bulbar
muscles similar to the pattern in CCD is observed in
another subgroup of MmD; some patients may show
additional marked distal weakness and wasting, predom-
inantly affecting the hands (moderate form of MmD with
hand involvement) [23,24]. As in CCD, exercise-induced
myalgia is common, and cryptorchism may be an addi-
tional feature in males (personal observation). The pat-
tern of selective involvement on muscle imaging is similar
to that observed in classic CCD caused by dominant RYR1
mutations [21,23-25] (Figure 1), and distinct from the
selective muscle involvement described in myopathies
due to recessive mutations in the SEPN1 gene [26]. The
latter two groups may form part of a clinical spectrum
rather than distinct entities, as suggested by the observa-
tion of extra-ocular muscle involvement evolving over
time in patients with the moderate form of MmD [21].
Few severely affected cases have been reported with ante-
natal onset, generalized arthrogryposis, dysmorphic fea-
tures and mild to moderate reduction of respiratory
function [8].
Respiratory impairment is marked in the classic pheno-
type of MmD but usually mild or absent in other forms.
Cardiac, mainly right ventricular impairment, is usually
secondary to marked respiratory involvement [7] and
therefore limited to the classic phenotype of MmD; con-
genital cardiac defects, particularly mitral valve prolapse,
have been reported in few patients [1].
The association with malignant hyperthermia (MH) is not
as well documented as in CCD due to dominant RYR1
mutations [27], but clinical MH episodes have been rec-
ognized in few cases with MmD [28,29]; minicores have
also been noted in muscle biopsies from families with
MH susceptibility due to RYR1 mutations but no other
clinical features of a congenital myopathy [30,31]. Precau-
tions during general anaesthesia such as avoidance of
MH-triggering agents such as volatile anaesthetics or mus-
cle relaxants should therefore be taken in MmD patients,
particularly those with likely involvement of the RYR1
gene.
For diagnostic clues to aid the sometimes difficult distinc-
tion between SEPN1- and RYR1-related forms of MmD see
Table 1.Orphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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Aetiology
The marked clinical variability of MmD is reflected in
genetic heterogeneity: Recessive mutations in both the
selenoprotein N (SEPN1)  [13] and the skeletal muscle
ryanodine receptor (RYR1) gene [17,23-25,32] have been
recently identified in clinically distinct subgroups; most
reports of dominant inheritance predate molecular reso-
lution of the condition [9,33-38] and may have been due
to dominant mutations in the RYR1 gene or other genes
giving rise to cores on muscle biopsy.
The selenoprotein N (SEPN1) gene on chromosome 1p36
was considered as a candidate for MmD because of the
considerable clinical and histopathologic overlap
between the classic phenotype of MmD (see paragraph
above on clinical description) and congenital muscular
dystrophy with rigidity of the spine (RSMD) due to SEPN1
mutations [39]; both conditions share a similar pheno-
type with marked axial weakness, spinal rigidity, early sco-
liosis and respiratory impairment, and histopathologic
features of RSMD may be rather more myopathic than
dystrophic, with typically a normal creatine kinase (CK).
More than 30 SEPN1 mutations associated with a congen-
ital myopathy phenotype have been identified to date and
account for around 50% of cases with the classic pheno-
type of MmD [13]. SEPN1 mutations in RSMD and MmD
are predominantly truncating, with few missense muta-
tions typically affecting functionally important domains
of the protein. Homozygous mutations are unexpectedly
common even in families from non-consanguineous
backgrounds, due to the presence of few founder muta-
tions in different European populations. Selenoprotein N,
a glycoprotein localized in the endoplasmic reticulum,
belongs to a family of proteins mediating the effect of
selenium [for review, [40]] and is involved in various anti-
oxidant defence systems and several metabolic pathways.
Abundant expression in fetal muscle precursor cells [41]
indicates a role in myogenesis, also supported by the more
recent finding of marked myofibrillar alterations in the
zebrafish embryo following inhibition of the SEPN1 gene
[42]. Although the precise function of selenoprotein N in
muscle remains unclear, possible involvement in calcium
homoeostasis is suggested by a structural motif similar to
those found in calcium-binding proteins [39].
Clinical subgroups other than the classic phenotype of
MmD have now been associated with recessive
homozygous and compound heterozygous mutations in
the skeletal muscle ryanodine receptor (RYR1)  gene.
Homozygous  RYR1  mutations have been identified in
consanguineous families of different ethnic background
with the moderate form (with or without hand involve-
ment) of MmD [23,24]; despite distinct histopathologic
appearance, clinical features and findings on muscle
imaging were similar to those observed in CCD secondary
to heterozygous dominant RYR1  mutations. A cryptic
splice site mutation in RYR1 intron 101 was identified in
a severely affected isolated case from a consanguineous
Tunisian family with MmD and ophthalmoplegia [22],
resulting in a marked depletion of the normal RYR1 tran-
script, probably explaining the severe phenotype; both
parents were asymptomatic carriers. RYR1  involvement
was also suggested by linkage evidence and subsequent
mutational analysis in four additional families with MmD
and opthalmoplegia [17], including the original family
reported by Swash and Schwartz [18]. In addition to com-
pound heterozygosity for recessive RYR1 mutations in one
case, heterozygous RYR1  mutations inherited from an
asymptomatic father and expressed on a haploinsufficient
background were identified in three families; this has now
been attributed to epigenetic allele silencing of the RYR1
gene as a novel mechanism in the pathogenesis of core
myopathies [43]. The RYR1 gene is also a likely candidate
for the severe form of MmD with neonatal onset and
Selective muscle involvement in RYR1-related central core  disease (CCD) and multi-minicore disease (MmD) Figure 1
Selective muscle involvement in RYR1-related central core 
disease (CCD) and multi-minicore disease (MmD). Muscle 
MRI of the thigh, T1-weighted images. A) A transverse sec-
tion from the proximal thigh in a 12-year-old patient with 
central core disease (CCD) due to a dominant mutation in 
the skeletal muscle ryanodine receptor (RYR1) gene. There is 
a distinct pattern of selective involvement characterized by 
marked increase in signal within the vasti, sartorius (S), and 
adductor magnus (AM), and relative sparing of the rectus 
femoris (RF), adductor longus (AL), gracilis (G), and ham-
string muscles. B) A transverse section from the proximal 
thigh in a 17-year-old girl with Multi-minicore disease due to 
a homozygous recessive RYR1 mutation demonstrating a 
comparable pattern of selective involvement. * Reprinted 
from [24] Neurology 2002 Jul 23;59(2):284–7. Jungbluth et 
al.: Autosomal-recessive inheritance of RYR1 mutations in a 
congenital myopathy with cores.With permission from 
Lippincott Williams & Wilkins (LWW).Orphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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arthrogryposis, considering phenotypic overlap with the
form of CCD with fetal akinesia sequence [44].
RYR1 is organized in 106 exons [45] and encodes the skel-
etal muscle ryanodine receptor (RyR1), the principal, lig-
and-gated sarcoplasmic reticulum calium release channel
with a crucial role in excitation-contraction (E-C) cou-
pling by regulating cytosolic Ca2+ levels. RyR1 calcium
release is primarily triggered by voltage-induced confor-
mational changes of the abutting dihydropyridine
(DHPR) receptor, and secondarily by a number of exoge-
neous and endogeneous effector molecules [for review,
[46]]. RyR1 N-terminal portions are myoplasmic and con-
stitute the visible foot structure that interacts with the
DHPR receptor, whereas the actual calcium release chan-
nel is located in the C-terminal part of the protein [47].
The large majority of the more than 100 RYR1 mutations
identified to date were dominant mutations associated
with malignant hyperthermia susceptibility (MHS) and
central core disease (CCD) phenotypes, typically clustered
in the cytoplasmic N-terminal (MHS/CCD region 1,
amino acids 35 – 614; mainly MHS), the central (MHS/
CCD region 2, amino acids 2163 – 2458; mainly MHS)
and the C-terminal (MHS/CCD region 3, amino acids
4550 – 4940; mainly CCD) domains of the protein [for
review, [48]; also [32,49]]. In contrast, recessive RYR1
mutations associated with MmD have so far only been
identified in a small number of families [17,22-24,32]
and appear to be distributed throughout the entire RYR1
gene (Figure 2); compound heterozygosity for mutations
affecting MHS-related domains of the protein associated
with a MmD phenotype has been recognized [17,32]. The
majority of MmD-related RYR1 mutations were missense
mutations; few intronic splicing mutations have been
recently reported [17,22,32].
In contrast to RYR1 mutations associated with CCD and
MHS, MmD-associated RYR1 mutations have only been
recently studied and specific functional consequences are
currently only imperfectly understood. The functional
effects of RYR1 mutations associated with CCD and MHS
have been extensively investigated in response to the in
vitro contracture test (IVCT), in cultured myotubes from
patients and in various homologous and heterologous
expression systems, resulting in a tentative understanding
of the molecular pathophysiology implicated in those
phenotypes [for review, [48]]. MH-related RYR1  muta-
tions are thought to result in hypersensitivity of the RyR1
channel, lowering the activation threshold to lower ago-
nist concentrations, whereas CCD-related RYR1  muta-
tions appear to reflect defective intracellular Ca2+
homoeostasis, either due to depletion of intracellular Ca2+
stores ("leaky channel hypothesis") [50] or because of
impaired channel efficiency at transporting Ca2+ after acti-
vation via depolarization ("E-C uncoupling hypothesis")
[51].
The few functional data available to date on MmD-related
RYR1 mutations [52-54] suggest a wide variety of patho-
genetic mechanisms underlying this phenotype: based on
studies of Ca2+ homoeostasis in EBV-immortalized lym-
phoblasts from patients [52], the previously reported
homozygous P3527S substitution [23] was demonstrated
to result in decreased stimulated Ca2+ release despite pre-
served intracellular Ca2+ stores (suggestive of an uncou-
pled channel), whereas the V4849I substitution [24] was
associated with a small but significant effect on resting
Ca2+ concentrations. E-C uncoupling was also indicated
by complete loss of Ca2+ conductance in recombinant
mutant RyR1 channels expressing a Arg109Trp substitu-
tion [53] previously associated with a MmD and ophthal-
moplegia phenotype [17]. Marked reduction of the
amount of the RyR1 protein in some individuals [22,32]
suggests that MmD-related RYR1  mutations may affect
protein expression and stability as much as function.
Additional work will be required to further elucidate the
Table 1: Clinical and histopathologic features which may aid the distinction between SEPN1-related and RYR1-related forms of Multi-
minicore disease (MmD).
Feature SEPN1-related MmD RYR1-related MmD
Clinical
Extraocular involvement - ++
Bulbar involvement + +
Respiratory involvement +++ +
Scoliosis +++ ++
Malignant hyperthermia susceptibility - +
Histopathology
Type 1 predominance/uniformity + +++
Increase internal nuclei + +++
Multiple large cores ("multicores") + +++
Numerous small cores ("minicores") +++ +
(-) = feature not reported, (+) = feature reported, (++) = common feature, (+++) = very common featureOrphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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molecular mechanisms underlying RYR1-related MmD,
and may contribute to the understanding of E-C coupling
and RyR1 interactions.
Diagnostic methods
Multi-minicore Disease (MmD) is a histologic diagnosis
established on muscle biopsy. MmD is characterized by
multifocal, well-circumscribed areas with reduction of
oxidative staining and low myofibrillar ATPase [1].
In contrast to central cores, minicores extend only for a
short distance along the longitudinal axis of the muscle
fibre, are typically unstructured and may affect both type
1 and type 2 fibres [55]; a peculiar picture described as
"focal loss of crossstriations" in muscle fibres has been
reported in some families [18,19]. Cores may vary sub-
stantially in size and morphology (Figure 3), to some
extent depending on the genetic background: SEPN1-
related MmD is typically associated with numerous small
lesions scattered throughout the muscle fibre ("mini-
cores"), whereas multiple larger lesions ("multicores") are
more commonly seen in forms of MmD related to reces-
sive mutations in the RYR1 gene; in the latter group, there
may be a continuum with the histopathologic appearance
Schematic representation of the skeletal muscle ryanodine receptor (RYR1) gene and distribution of dominant and recessive (*)  mutations associated with central core disease (CCD, in black) and Multi-minicore Disease (MmD, in red) Figure 2
Schematic representation of the skeletal muscle ryanodine receptor (RYR1) gene and distribution of dominant and recessive (*) 
mutations associated with central core disease (CCD, in black) and Multi-minicore Disease (MmD, in red). Dominant muta-
tions associated with a CCD phenotype predominantly affect the RYR1 C-terminal domain encoding the calcium release chan-
nel pore of the ryanodine receptor protein, whereas recessive mutations predominantly associated with a MmD phenotype are 
distributed evenly throughout the gene. N-terminal, central and C-terminal mutational hotspots within the RYR1 gene are high-
lighted in grey. (Figure courtesy of Dr Haiyan Zhou)Orphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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of CCD, occasionally evolving over time as demonstrated
in patients on consecutive muscle biopsies [23,56]. Pre-
dominance or uniformity of hypotrophic type 1 fibres are
commonly associated and may precede the appearance of
more specific features [7,56,57]; these findings appear to
be more commonly observed in cases due to RYR1 muta-
tions compared to SEPN1-related MmD, where fibre typ-
ing is often preserved (Sewry, personal observation). A
potential overlap with the milder end of the congenital
muscular dystrophy spectrum suggested by the observa-
tion of whorled fibers, an increase in fat and connective
tissue and more dystrophic changes in some individuals
[13,55] was recently genetically confirmed by the identifi-
cation of recessive SEPN1 mutations in cases of classical
MmD and muscular dystrophy with early rigidity of the
spine, a mild form of congenital muscular dystrophy
[13,39].
On electron microscopy, minicores present as areas of
myofibrillar disruption and paucity of mitochondria,
often with degeneration of the sarcomeres and structural
changes of the sarcoplasmic reticulum and transverse
tubules [55]. The same biopsy may show different stages
of minicore formation, ranging from Z-line streaming
with preserved myofibrillar structure to areas with com-
plete loss of the sarcomeric architecture [1].
Histopathological features of Multi-minicore disease Figure 3
Histopathological features of Multi-minicore disease. NADH-TR (a–c) and cytochrome oxidase (COX) (d) stains, horizontal 
(a,c) and transverse (b,d) sections from a 3-year-old (a–b) and a 9-year-old girl (c–d) from different families. Predominance of 
darker staining type 1 fibres is prominent in both patients, whilst appearance of core lesions is widely variable, ranging from 
numerous small lesions of limited extent ("minicores") (a-b) to few multiple large lesions often extending throughout the entire 
fibre diameter ("multicores") (c, →) and occasionally affecting the same area in adjacent fibres (d, →). Whilst "minicores" are 
more frequently found in SEPN1-related MmD, the latter appearance is more typical of the RYR1-related form and indicates a 
possible histopathologic continuum with central core disease (CCD) due to mutations in the same gene.Orphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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Limited immunohistochemical studies in MmD suggest
sarcoplasmic reticulum and desmin abnormalities corre-
sponding to those observed in CCD [58]; as with central
cores, minicores stain also strongly positive with antibod-
ies to the actin cross-linking protein filamin C in a non-
specific manner [59]. A more recent study suggests distur-
bance of Ca2+ -related proteins as a useful immunohisto-
chemical marker to distinguish RYR1-related forms from
SEPN1-related forms of MmD [60].
In cases with equivocal clinical or histopathological fea-
tures,  muscle MR imaging may complement clinical
assessment and aid the choice of appropriate genetic test-
ing, as the pattern of selective muscle involvement associ-
ated with RYR1 mutations [25] (Figure 1) is distinct from
that observed in SEPN1-related cases [26] or other con-
genital myopathies such as nemaline myopathy [61].
Differential diagnosis
The finding of cores on muscle biopsy is non-specific and
may be observed in a number of different contexts,
including clinical conditions with no or little associated
weakness and as an additional finding in other neuromus-
cular disorders.
Minicores as a non-specific finding on muscle biopsy
have been reported in healthy probands following eccen-
tric exercise (i.e., lengthening during activity) [62] and on
muscle biopsies from families with MH susceptibility due
to RYR1 mutations but no other clinical features of a con-
genital myopathy [30,31]; they may occur in other con-
texts such as dystrophy, denervation, inflammatory and
endocrine myopathies [for review, [1]] and primarily met-
abolic conditions such as type III glycogenosis [63] or
short-chain acyl-CoA dehydrogenase (SCAD) deficiency
[64]. It is therefore important to emphasize that the pres-
ence of minicores on muscle biopsy without associated
weakness or in the presence of other disease causes is not
sufficient to constitute a diagnosis of MmD. Single MmD
families have been reported with multiple pterygium syn-
drome [65] and a complex dysmorphic syndrome featur-
ing short stature, musculoskeletal anomalies, mental
retardation, and pituitary hypoplasia with hypogonado-
trophic hypogonadism [66]; the genetic basis for this
association is currently unclear.
The occurrence of minicores on muscle biopsy in associa-
tion with features of other congenital myopathies such
as central cores, nemaline rods or central nuclei has been
well-documented in the pre-molecular era [14,33,67-72]
and is currently only partially genetically resolved. Core-
like structures, with or without additional nemaline rods,
have been reported in association with dominant muta-
tions in the ACTA1 gene [73,74], and there is recent evi-
dence that recessive mutations in the RYR1 gene may give
rise to the appearance of centronuclear myopathy with or
without additional cores on muscle biopsy [6]. As mini-
cores are thus not specific, the diagnosis of MmD requires
the presence of minicores as the predominant feature on
muscle biopsy in conjunction with suggestive clinical fea-
tures.
The distinction from central core disease (CCD) due to
dominant RYR1 mutations may be particularly challeng-
ing in the subset of MmD due to recessive mutations in
the same gene, as histopathologic features in the latter
groups and CCD may represent part of a continuous his-
topathologic spectrum rather than distinct entities [56].
However, MmD-associated recessive RYR1 mutations give
rise to clinical features such as external ophthalmoplegia,
bulbar involvement and a moderate degree of respiratory
impairment not commonly observed in typical dominant
CCD. Although recessively inherited RYR1  mutations
appear to be more closely associated with the histopatho-
logic appearance of MmD rather than CCD, dominant
RYR1 mutations may occasionally give rise to minicores
on muscle biopsy [56] and may have accounted for the
small number of MmD pedigrees with apparent auto-
somal dominant inheritance reported in the pre-molecu-
lar area. In addition, the histopathologic appearance of
RYR1-related MmD may evolve into the classic picture of
CCD on follow-up biopsies later in life [23].
Although cardiac impairment secondary to respiratory
involvement is not uncommonly observed in SEPN1-
related MmD, primary cardiomyopathies have not been
reported in genetically confirmed cases of MmD due to
mutations in the SEPN1 or RYR1 genes. However, some
myopathies with primary cardiac involvement and a dis-
tinct genetic background may feature minicores as an
additional histopathologic finding. A rare autosomal
dominant myopathy with associated dilated cardiomyop-
athy and both central and minicores on muscle biopsy has
been attributed to mutations in the skeletal muscle α-
actin  (ACTA1)  gene [74], whereas autosomal recessive
mutations in the titin (TTN) gene were recently identified
in a novel early-onset myopathy with minicores,
increased central nuclei, dystrophic features and a fatal
cardiomyopathy [75].
In addition, prominent desmin accumulation in skeletal
and cardiac muscle fibres from other patients with mini-
cores on muscle biopsy and a primary cardiomyopathy
[76] may point to primary involvement of the desmin
(DES) or related genes; also, mutations in the lamin A/C
(LMNA) gene, a common cause of various muscular dys-
trophy and cardiac phenotypes [for review, [77]], may
also be associated with core-like structures on muscle
biopsy and have to be considered in cases with minicores
and prominent cardiac involvement. It is likely that theOrphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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few families with primary cardiomyopathies in associa-
tion with minicores on muscle biopsy reported in the pre-
molecular area [9,11,34,76,78] may have carried muta-
tions in above genes rather than the SEPN1 and RYR1
genes now firmly associated with MmD.
Management
No curative treatment is currently available for MmD and
management is mainly supportive based on a multidisci-
plinary approach.
Regular physiotherapy is aimed at promoting endurance,
preservation of muscle function and the prevention of
contractures, particularly those of the tendon Achilles.
Marked axial involvement is common, particularly in the
classic form of MmD secondary to SEPN1 mutations, and
exercises promoting truncal stability such as swimming
and riding [79] may be particularly recommended. Scolio-
sis is almost invariable in the classic form of MmD and in
most cases eventually will have to be managed surgically,
considering that conservative approaches are often unsuc-
cessful due to the progressive nature of the deformity. As
in other neuromuscular conditions, mobilization follow-
ing surgery ought to be early in order to avoid the detri-
mental effects of prolonged immobilization on muscle
strength. Independent ambulation may be promoted by
appropriate rehabilitative measures such as provision of
weight bearing calipers in the most severe cases where
walking can not be achieved without additional support.
Severe respiratory impairment is almost invariable in the
classic phenotype of MmD secondary to SEPN1 mutations
and has to be anticipated with a high degree of suspicion,
as most patients remain independently mobile with only
little functional impairment whilst already developing
respiratory failure [7,8]. Patients have to be specifically
questioned for symptoms suspicious of nocturnal hypov-
entilation such as early morning headaches, loss of appe-
tite and daytime drowsiness; respiratory capacity ought to
be monitored regularly and annual overnight oxygen sat-
uration studies performed if forced vital capacity (FVC) is
less than 60% of the expected value, and more frequently
if FVC is less than 40% [80]. Respiratory impairment in
other forms of MmD due to RYR1 mutations is usually
less severe or absent, but considering the not negligible
risk monitoring of respiratory function according to the
principles outlined above is advisable. In all forms of
MmD, respiratory infections should be treated actively.
Right ventricular impairment secondary to respiratory
failure has been reported in the classic phenotype of
MmD and patients with those clinical features ought to
have regular cardiac assessments including cardiac ultra-
sounds. A primary cardiomyopathy has not yet been
reported in patients with confirmed mutations in the
SEPN or RYR1 genes; however, cores on muscle biopsy are
non-specific and may be found as an additional feature in
patients with primary cardiomyopathies due to mutations
in the DES, TTN, LMNA and ACTA1 genes (see paragraph
on differential diagnosis). Cardiac ultrasound studies
therefore ought to be considered in cases where clinical
features are unusual and mutations in the SEPN1  and
RYR1 genes have been excluded.
Patients with MmD secondary to mutations in the RYR1
gene may be at risk of malignant hyperthermia reactions,
an abnormal response to muscle relaxants such as succi-
nylcholine and volatile anaesthetics [27,81], as has been
reported in few cases [28,29]; minicores on muscle biopsy
have also been noticed in few patients with RYR1-related
MH susceptibility but no other clinical features of a con-
genital myopathy [30,31]. Although the association with
MH susceptibility is not as clearly documented as in CCD
and has been excluded by in vitro contracture testing in
some families [23], precautions such as avoidance of
potentially MH-triggering agents and availability of the
RyR1 antagonist dantrolene should be taken during gen-
eral anaesthesia.
The β-agonist salbutamol has been recently studied as a
pharmacological agent in the treatment of RYR1-related
myopathies with encouraging results [82], however,
results of this pilot study will have to be validated in a
larger randomized controlled trial as a basis for future rec-
ommendations.
Genetic counselling
Genetic counselling should be offered to all families and
individuals in whom a diagnosis of MmD has been made.
SEPN1-related MmD and the majority of cases associated
with mutations in the RYR1 gene are inherited as an auto-
somal recessive trait; only few families with multi-mini-
cores on muscle biopsy and dominant inheritance have
been documented.
Mutational analysis of the SEPN1 gene is now offered as a
diagnostic service in most countries. Diagnostic RYR1
screening of selected exons has been established for
malignant hyperthermia patients by a number of labora-
tories associated with the European Malignant Hyperther-
mia Group (EMHG) [83] however, patients with MmD
are likely to require sequencing of the entire RYR1 coding
sequence currently not widely available. Unlike muta-
tions associated with a CCD phenotype, MmD-related
RYR1 mutations appear to be distributed throughout the
RYR1 coding sequence [17,32] and a mutational strategy
focusing on mutational hotspots is therefore not feasible.
The recent finding of haploinsufficiency secondary to epi-
genetic allele silencing in RYR1-related phenotypes [43]
poses a particular challenge and should prompt screeningOrphanet Journal of Rare Diseases 2007, 2:31 http://www.OJRD.com/content/2/1/31
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of muscle-derived cDNA in cases where an affected child
has inherited a mutation from an unaffected parent.
Prognosis
Respiratory impairment is the main prognostic factor in
SEPN1-related MmD and has to be managed pro-actively;
patients can usually be maintained on nocturnal non-
invasive ventilation for many years without major func-
tional deterioration.
The forms of MmD due to recessive RYR1 mutations are
usually associated with a mild to moderate degree of dis-
ability and carry an overall favourable prognosis, and,
with the exception of the most severely affected neonatal
cases, almost all patients achieve the ability to walk inde-
pendently. The course of RYR1-related MmD in child-
hood and adolescence is static or only slowly progressive
[17,32], but the absence of larger long term follow-up
series makes it difficult to comment on the further course
into adulthood.
Unresolved questions
The precise molecular mechanisms underlying MmD are
currently only partially understood. Recent limited func-
tional studies suggest that recessive RYR1 mutations may
affect function of the tetrameric RyR1 protein only in the
homozygous state; this may be modulated through the
effect on the binding of accessory and regulatory proteins
involved in channel kinetics. More extensive functional
studies are required to further delineate specific genotype-
phenotype correlations in MmD and are likely to advance
our understanding of excitation-contraction (E-C) cou-
pling as a potential basis for future rational therapeutic
approaches.
While the functional effects of RYR1 mutations associated
with CCD, MHS and MmD are at least partially under-
stood, the precise molecular mechanisms in the patho-
genesis of SEPN1-related MmD remains unclear; a
calcium-binding motif within the selenoprotein N pro-
tein suggests that intracellular Ca2+ handling may also be
affected in this subgroup of MmD and points at a com-
mon pathway in the pathogenesis of core formation.
A proportion of patients with typical features of MmD do
not harbour mutations in the RYR1 or SEPN1 genes and
this group is still awaiting genetic resolution.
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